Tuesday, July 1, 2025 7/1/2025

Genetic Factors for Glaucoma in the OHTS; Risk, Progression and Mechanism

Award Number: R01EY035266
ORGANIZATION: NATIONAL EYE INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/30/2023
PERIOD OF PERFORMANCE END DATE: 01/31/2028

Group Awards By:

View Award Description

Genetic Factors for Glaucoma in the OHTS; Risk, Progression and Mechanism - ABSTRACT Glaucoma is a common cause of severe vision loss, characterized by the progressive loss of retinal ganglion cells. Several large genome-wide association studies (GWAS) for primary open angle glaucoma (POAG) have been performed to date and have discovered over 127 risk factor genes. The mechanism by which these genes lead to POAG is almost completely unknown. Our proposal seeks to 1) translate these risk factor gene discoveries into useful data for patients and their doctors and 2) determine the mechanisms by which risk factor genes confer risk. This proposal will leverage the results of prior GWAS studies along with the unmatched, 20-years of prospective clinical data from the Ocular Hypertension Treatment Study (OHTS) to develop a POAG risk calculator that includes both clinical and genetic risk factors that will be useful to patients and doctors (AIM1A). We will also conduct association studies of the OHTS cohort to identify genetic risk factors for rapid progression of POAG as measured by visual field parameters, with validation in a local Iowa cohort (AIM1B). Identifying genes associated with progression of glaucoma has great potential to personalize and guide glaucoma management. We will also investigate the functional consequences of specific glaucoma risk alleles with a range of complementary technologies. AIM2A will test the effects of risk alleles on gene expression and pathways with studies of genotyped human donor eyes using single-cell RNA sequencing (scRNAseq). Immunohistochemistry and ELISA of genotyped human donor eyes will also be used to determine the effects of risk alleles on the abundance and localization of the proteins they encode. Finally, in AIM2B will use BiT- STARR-seq to locate the specific variants (SNPs) in glaucoma loci that confer risk for glaucoma. These studies will begin to define the precise molecular steps that connect the presence of specific genetic risk factors in one’s genome to the development of glaucoma. Our proposal will lead to improved tools for ascertainment of a patient’s risk for POAG or risk for rapid worsening of POAG that can be readily transferred to clinicians in the form of better diagnostic and prognostic tools. Our proposal will also define the specific mechanisms by which risk factor alleles alter gene expression in key tissues (retinal ganglion cells), which will identify disease mechanisms and new therapeutic targets to facilitate development of targeted treatments. Our proposal has great potential to improve glaucoma care and reduce vision loss.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $400,478 )
2025	2025	THE UNIVERSITY OF IOWA	105 JESSUP HALL	IOWA CITY	IA	52242	JOHNSON	USA	Vision Research	000	3	1/16/2025	NON-COMPETING CONTINUATION	$400,478
														Subtotal = $400,478

Issue Date FY: 2024 ( Subtotal = $400,478 )
2024	2024	THE UNIVERSITY OF IOWA	105 JESSUP HALL	IOWA CITY	IA	52242	JOHNSON	USA	Vision Research	000	2	2/7/2024	NON-COMPETING CONTINUATION	$400,478
														Subtotal = $400,478

Issue Date FY: 2023 ( Subtotal = $414,353 )
2023	2023	THE UNIVERSITY OF IOWA	105 JESSUP HALL	IOWA CITY	IA	52242	JOHNSON	USA	Vision Research	000	1	8/31/2023	NEW	$414,353
														Subtotal = $414,353

Grand Total All Awards = $1,215,309

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Genetic Factors for Glaucoma in the OHTS; Risk, Progression and Mechanism

Award Number: R01EY035266

ORGANIZATION: NATIONAL EYE INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/30/2023

PERIOD OF PERFORMANCE END DATE: 01/31/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer